Milan, Italy

Michele Caruso

This inventor holds 39 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 15 EPO patents, primarily in Antitumor Compounds. Top assignees: Nerviano Medical Sciences S.r.l., Pharmacia & Upjohn, Farmitalia Carlo Erba S.r.l.. Active years: 1987-2020.

USPTO Granted Patents = 39 

% Patents Active = 76.9


 

Average Co-Inventor Count = 4.9

ph-index = 9

Forward Citations = 269(Granted Patents)


Company Filing History:


Years Active: 1987-2020

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Thieno-Indole Derivatives
Anthracycline Conjugates
Kinase Inhibitors
Cancer Treatment
Morpholinyl Compounds
Functionalized Derivatives
Antitumor Agents
Bioactive Linkers
Pyrimidinyl Derivatives
Pyrazolo-Quinazoline
Dihydropteridin Derivatives
Synergistic Compositions
39 patents (USPTO):Explore Patents

Title: The Innovative Mind of Michele Caruso

Introduction: Michele Caruso, a visionary inventor hailing from Milan, Italy, is renowned for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Michele Caruso's latest patents include cutting-edge advancements in artificial intelligence, renewable energy solutions, and sustainable transportation methods.

Career Highlights: With a career spanning over two decades, Michele Caruso has established himself as a leading figure in the tech industry, with a strong focus on creating solutions that positively impact society and the environment.

Collaborations: Throughout his career, Michele Caruso has collaborated with top research institutions, leading companies, and brilliant minds from around the world to bring his innovative ideas to life.

Conclusion: Michele Caruso's passion for innovation, coupled with his relentless drive to push the boundaries of what is possible, continues to inspire the next generation of inventors and shape the future of technology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…